The ATM is pleased to hear that British Columbia has announced a new Life Sciences and Biomanufacturing Strategy as part of the StrongerBC Economic Plan.
The Life Sciences and Biomanufacturing Strategy will secure B.C.’s position as a leading global hub for life sciences and biomanufacturing and develop commercial-scale biopharmaceutical and medical manufacturing. By consciously investing in people and infrastructure, the province will tapping into the potential of the industry value chain spanning the timeline from discovery to clinical trials and manufacturing.
Part of this plan plan is to target local companies focused on innovation. For example, the province is investing $10 in a new adMare Bioinnovations wet lab facility with cutting-edge equipment. Together with announcements such as the National Biomanufacturing Training Centre (NBTC), the provincial commitment to excellence in the life science sector is prominent. The Academy of Translational Medicine is excited to hear about the announcement of the Life Sciences and Biomanufacturing Strategy and what it will mean for translational medicine efforts in the province.
“The launch of the B.C. Life Sciences and Biomanufacturing Strategy is a significant step toward improving health care and patient outcomes by investing in clinical trials capacity. By expanding B.C.’s clinical trials capacity, we are creating opportunities for more innovative companies to anchor and grow in B.C., which will benefit patients by increasing access to new treatments and therapies.” – Adrian Dix, Minister of Health.
Read the announcement here and watch the video below!